J&J robotic surgery device wins US FDA marketing authorization

• The Ottava system is authorized for upper abdominal procedures including gastric bypass, gastrectomy, gallbladder removal, gastric sleeve surgery, appendectomy, and hiatal hernia repair
• J&J will initiate a limited U.S. commercial launch with select customers as it works to expand into additional medical indications and regulatory markets
• The authorization allows J&J to compete in the soft-tissue robotic surgery market, which has been dominated by established players

J&J Robotic Surgery Device Wins FDA Marketing Authorization

Johnson & Johnson (J&J) announced Wednesday that the U.S. Food and Drug Administration has granted marketing authorization for its Ottava robotic surgical system, enabling the healthcare giant to enter the competitive soft-tissue robotic surgery market.

Key Details:

The Ottava system received clearance for use in multiple general surgery procedures targeting the upper abdomen, including:

• Gastric bypass
• Gastrectomy
• Gallbladder removal
• Gastric sleeve surgery
• Appendectomy
• Hiatal hernia repair

Market Implications:

This authorization marks a significant milestone for J&J as it positions itself to compete in the robotic surgery sector, a market currently dominated by established players like Intuitive Surgical. The entry of a major healthcare conglomerate with J&J's resources and distribution capabilities could intensify competition and potentially accelerate innovation in robotic-assisted surgical procedures.

Rollout Strategy:

J&J plans to initiate a controlled U.S. commercial launch with select customers rather than an immediate broad-market release. The company indicated it will work simultaneously to expand the system's approved indications and pursue regulatory clearance in additional international markets, suggesting a measured, strategic approach to market penetration.

The timing of this authorization positions J&J to capitalize on growing demand for minimally invasive surgical solutions, which offer benefits including reduced patient recovery times and improved surgical precision. The company's phased launch strategy suggests a focus on gathering real-world data and refining commercial processes before scaling operations more broadly.